Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2
Obesity Management for Kidney TRANSPLANTation: a Vanguard Study for an Innovative Randomized Controlled Trial, Embedded in Routine Care (OK-TRANSPLANT 2)
Western University, Canada
60 participants
Sep 26, 2024
INTERVENTIONAL
Conditions
Summary
OK-TRANSPLANT 2 is a vanguard study for a large randomized, pragmatic, open-label trial. We will randomize participants with obesity, high-risk CKD/dialysis who are hoping for lose weight for the purpose of kidney transplant. Subjects will either be enrolled on a virtual weight management program or continue their usual care.
Eligibility
Inclusion Criteria3
- Adults aged 18 years or older
- BMI \> 35 kg/m\^2
- \>10% risk of ESKD requiring renal replacement therapy over 2 years or receiving dialysis
Exclusion Criteria6
- Known contraindication to a GLP-1RA
- Type 1 diabetes
- No access to semaglutide via drug coverage
- Absolute contraindication to kidney transplant
- Pregnant, breastfeeding or planning to become pregnant
- Currently in a GLP-1RA or GLP-1RA/GIP study or planning to be in one
Interventions
Maximum tolerated dose of semaglutide subcutaneously once weekly. Maximum dose of 2.0 mg.
Virtual meeting with intervention coach once every 4 weeks for 6 months, where the coach will discuss the goals and progress with participant, nutritional advice, exercise advice, and motivational support.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06396416